What ADHD medications are available in Canada for adults?

Health Canada authorizes ADHD medications in two broad classes

Every medication marketed in Canada for ADHD has gone through Health Canada's authorization process and appears in the federal Drug Product Database, which lists marketed status, approved uses, and the product monograph for each entry. Broadly, authorized products fall into stimulant medications and non-stimulant medications, which work through different mechanisms and are prescribed for different reasons depending on someone's health history and response.

This national authorization is separate from provincial coverage decisions, which is a distinction that comes up often when people compare what's technically available with what a specific drug plan will pay for. A product can be fully authorized and legally prescribed everywhere in Canada while still being expensive or restricted on a specific plan.

Stimulant formulations come as short-acting or long-acting

Short-acting stimulant formulations act quickly but wear off within a few hours, so they are usually taken more than once a day to maintain coverage through work, school, or other demands. Long-acting formulations are designed to release gradually and typically cover a working day from a single morning dose. Both are scheduled as controlled drugs in Canada, which affects how pharmacies dispense and refill them and adds verification steps a routine prescription doesn't require.

Long-acting formulations are generally favoured for daily use, since a single morning dose reduces the number of times medication needs to be carried, stored, or taken during the day. Short-acting formulations still have a role, sometimes as a top-up later in the day or during initial titration, when a prescriber wants to see how a smaller, faster-acting dose is tolerated before committing to a full-day formulation.

Several distinct non-stimulant classes exist for adults

Non-stimulant options include a class that works on a different brain chemical pathway than stimulants, extended-release medications originally developed for blood pressure that are sometimes used for ADHD symptoms, and certain antidepressant-class medications used off-label in specific situations. None are scheduled as controlled drugs, and each has its own timeline, side effect pattern, and monitoring needs, which a prescriber reviews against personal and family health history before recommending one.

• A non-stimulant class targeting a different brain chemical pathway than stimulants
• Extended-release blood-pressure-class medications sometimes used for ADHD symptoms
• Certain antidepressant-class medications used off-label in specific situations

What is authorized federally is not the same as what your plan covers

Health Canada authorization only confirms a product can be legally sold and prescribed in Canada. Whether a specific product is listed, requires special approval, or is not covered at all depends on your provincial drug plan or private insurer. Ontario residents can check current coverage status for a specific product directly, and other provinces publish similar formulary lookups. Coverage details change, so check your plan before assuming a product is included, especially if you're comparing options ahead of an assessment.

The list of authorized products changes as new approvals and shortages occur

Health Canada updates the Drug Product Database as new products are authorized, discontinued, or affected by a supply issue, and provincial formularies publish monthly updates on what is listed. A medication available today is not guaranteed to remain on a specific formulary indefinitely, which is one reason follow-up visits with a prescriber matter even once a working medication is found, rather than treating the first prescription as permanent.

Brand-name and generic versions are authorized and tracked separately

Health Canada's Drug Product Database lists a separate drug identification number for each brand-name product, each generic equivalent, and each strength, even when they contain the same active ingredient. This matters practically because provincial formularies sometimes list the generic version as the default covered option while treating the brand-name version as an extra-cost or non-listed choice, so two products that work the same way clinically can carry very different out-of-pocket costs.

This separation also explains why a pharmacy substitution during a shortage, switching a specific brand for its generic equivalent, does not usually require a new prescription, while switching between a stimulant and a non-stimulant class always does, since that changes what's actually being prescribed rather than which company made it.